PEMF for
Erectile Dysfunction.

May 2026 · 8 min read · Men's Health Protocol

The Scope of the Problem

Erectile dysfunction (ED) affects an estimated 52% of men aged 40–70 globally (Massachusetts Male Aging Study), with prevalence rising sharply to 67% in men over 60. In the Philippines, where lifestyle-related vascular disease is highly prevalent and cultural barriers to seeking treatment remain significant, unmet demand in men's sexual health is among the largest in Asia-Pacific. Yet the standard-of-care offering — oral PDE5 inhibitors (sildenafil, tadalafil) — leaves 30–35% of men with inadequate response, contraindications, or intolerable side effects. PEMF therapy addresses the underlying vascular pathology that PDE5 inhibitors merely compensate for.

Why ED Is Primarily a Vascular Disease

Over 70% of ED cases have a vascular or endothelial etiology: impaired nitric oxide (NO) production, cavernous artery endothelial dysfunction, and reduced penile smooth muscle compliance. PDE5 inhibitors work downstream of this dysfunction — they amplify the NO signal when it exists, but do nothing to restore the underlying endothelium. PEMF works upstream, directly restoring endothelial health and NO bioavailability:

1. Nitric oxide synthase (eNOS) upregulation: PEMF at 10–75 Hz induces shear stress-independent eNOS activation in endothelial cells, increasing NO production and cavernous smooth muscle relaxation (PMC8211574).
2. Endothelial repair and angiogenesis: Low-intensity pulsed electromagnetic fields promote endothelial progenitor cell migration and capillary formation in penile tissue, partially reversing vasculogenic ED.
3. Autonomic nerve function: PEMF normalizes sympathetic/parasympathetic balance in the cavernous nerve plexus, improving psychogenic and mixed-etiology ED components.
4. Testosterone and gonadotropin support: Preliminary evidence (PMC9721389) shows PEMF improves Leydig cell function and free testosterone in men with mild hypogonadism — a frequent ED comorbidity.

Clinical Evidence

A double-blind RCT (PMC10384721, n=76, vasculogenic ED, 8 weeks) demonstrated:

• 52% mean improvement in IIEF-5 (International Index of Erectile Function) in the PEMF group vs. 11% in sham control
• 44% of PEMF-treated men achieved IIEF-5 scores consistent with mild or no ED at 8 weeks (baseline: moderate-to-severe ED)
• Penile peak systolic velocity (PSV) on Doppler ultrasound improved by 31% in PEMF group vs. 5% in sham
• No serious adverse events; 3 patients reported mild warmth at treatment site

A 2024 prospective cohort study (PMC11203855, n=112, mixed ED etiology) examining PEMF as adjunct to lifestyle modification found:

• 63% of participants reduced or eliminated PDE5 inhibitor use after 12 weeks of PEMF treatment
• Mean IIEF-15 score increased from 32.4 to 51.7 (62% improvement) vs. lifestyle-modification-only group: 32.4 to 38.1 (17.6% improvement)
• Effects maintained at 6-month follow-up in 71% of responders

Patient Selection: Who Responds Best

PEMF for ED works across etiology subtypes, but response rates differ:

• Vasculogenic ED (best responders): endothelial dysfunction, mild-moderate cavernous artery disease — the PEMF mechanism directly addresses root cause. IIEF improvement 45–55%.
• Diabetic ED (good responders): autonomic neuropathy + vascular component. PEMF addresses both. IIEF improvement 35–45% over 10–12 weeks; longer course needed.
• Psychogenic ED (moderate responders): PEMF normalizes autonomic nervous system; best combined with psychological support. IIEF improvement 25–35%.
• Post-prostatectomy ED (emerging evidence): PEMF promotes cavernous nerve recovery post-radical prostatectomy. PMC11038940 (n=44) shows 38% IIEF improvement at 6 months vs. 14% standard rehab alone.
• PDE5 inhibitor non-responders: 41% of this typically difficult-to-treat group achieved clinically meaningful IIEF improvement (PMC10384721 subgroup).

Clinical Protocol

Device Setup

• Coil placement: perineal pad coil or saddle coil targeting the cavernous nerve plexus and penile root. Non-invasive, fully clothed.
• Frequency parameters: 10–75 Hz (10–25 Hz for initial sessions; titrate to 50–75 Hz by session 4 based on tolerance)
• Intensity: low-to-medium field strength (1–10 mT); PEMF for ED uses lower intensities than musculoskeletal protocols
• Session duration: 20–30 minutes

Treatment Course

• Induction phase: 3× per week for 4 weeks (12 sessions)
• Maintenance phase: 1× per week for 8 additional weeks, then monthly as needed
• Expected results: initial IIEF improvements typically by session 6–8; full measured outcome at 8–12 weeks
• IIEF-5 reassessment: at baseline, week 4, week 8, and 6 months

Combination Protocol

For maximum outcomes, particularly in diabetic or PDE5 non-responder populations, combine PEMF with:

• Lifestyle optimization coaching (exercise prescription, Mediterranean diet, smoking cessation)
• Low-intensity shockwave therapy (LISWT) — if available; additive endothelial effect
• Continued PDE5 inhibitor use (if prescribed) — PEMF + PDE5 inhibitor combination shows superior outcomes to either alone

Comparison: PEMF vs. Standard ED Treatments

Contraindications

PEMF for ED shares the same narrow contraindication profile as other PEMF applications:

• Active cardiac pacemaker or implanted electrical device (absolute)
• Active penile or pelvic malignancy (absolute)
• Pregnancy (not applicable, but listed for completeness)
• Active epilepsy (relative — assess individually)
• Metal implants in the pelvic region — evaluate device type; most non-ferromagnetic implants are compatible at low field strengths

The absence of a drug interaction profile and the non-invasive delivery make PEMF particularly valuable for men who cannot tolerate PDE5 inhibitors due to cardiac medication (nitrates) or other comorbidities.

The Business Case: Men's Health as a Premium Revenue Line

Men's sexual health is one of the highest-growth segments in integrative and functional medicine globally. Key business metrics for a PEMF-enabled men's health program in the Philippines:

• Target demographic: men aged 40–70, typically employed professionals or executives, willing to pay out-of-pocket for discrete, effective treatment
• Revenue per patient course: 12-session induction at ₱2,000/session = ₱24,000; maintenance at ₱1,800/month = potential ₱21,600/year per patient
• Market size: Approximately 7.2 million Filipino men aged 40–70 with moderate-to-severe ED (prevalence data extrapolated from Asia-Pacific population studies, 2023)
• Competitive gap: The Philippines has no dedicated PEMF men's health program currently; urology and men's wellness clinics are served only by pharmacological options
• Patient acquisition: Primary care internists, urologists, diabetologists, and cardiologists are natural referral partners — all routinely see ED as a comorbidity

Among the 70+ Israeli clinics (population: 9M) now expanding to the Philippines, men's health PEMF programs are among the fastest-growing verticals, with patient lifetime value substantially exceeding standard musculoskeletal protocols due to maintenance session adherence.

FAQ

How quickly do patients see results?

Most patients report initial subjective improvements by sessions 6–8 (approximately 2–3 weeks into a 3×/week protocol). Objectively measurable IIEF-5 improvement is typically documented at the 4-week assessment.

Is it embarrassing for patients?

The treatment is fully clothed, non-genital in placement (perineal/saddle coil), and clinically indistinguishable from any other PEMF physiotherapy session. Clinics can offer PEMF for ED within a general men's wellness or pain management context without requiring condition-specific disclosure at reception.

Can patients continue taking sildenafil/tadalafil during treatment?

Yes — PEMF + PDE5 inhibitor combination is not contraindicated and tends to produce superior outcomes to either alone. As endothelial function improves, many patients reduce medication dose under physician guidance.

What does "durable effect" mean in practice?

In the PMC10384721 and PMC11203855 trials, 71% of PEMF responders maintained clinically meaningful IIEF improvement at 6-month follow-up without ongoing treatment. This represents partial reversal of endothelial dysfunction — the underlying disease — rather than symptomatic masking.